Search Clinical Trials

Parkinson’s Foundation PD GENEration Genetic Registry

Radicava^®/(Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

HEALEY ALS Platform Trial – Regimen E

A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)

NeuroMuscular ObserVational Research (“MOVR Data Hub”)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Range Finding Clinical Trial to Evaluate the Tolerability, Safety, and Efficacy of PRAX-944 in the Treatment of Adults with Essential Tremor

A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants with amyotrophic lateral sclerosis, followed by an open-label extension

A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS)

An Observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment From Normal Aging

Statins Use in Intracerebral Hemorrhage Patients (SATURN)

Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery (ASPIRE)

A Phase 3b, Multicenter, Open-label Study to Evaluate the Immune Response to, and the Safety of, Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Oral Ozanimod Compared to Non-pegylated Interferon (IFN)-β or No Disease Modifying Therapy

This project is being done to learn how ozanimod impacts the body’s immune system responds to vaccines in subjects with relapsing multiple sclerosis (MS).

CorEvitas SPHERES (Synergy of Prospective Health and Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)

This project is being done to learn more about NMOSD, how doctors treat NMOSD, how well medications and other treatments work, the safety of those treatments, and to improve the care and outcomes of people with NMOSD.

A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

This project is being done to learn about changes in cognition that happen while being treated with Ozanimod.

A Phase III Multicenter Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Adult Patients With Relapsing Multiple Sclerosis

This project is being done to compare the effects, good or bad, of fenebrutinib versus teriflunomide on patients with RMS.

A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety Of Fenebrutinib Compared With Ocrelizumab in Adult Patients With Primary Progressive Multiple Sclerosis

This project is being done to compare the effects of fenebrutinib versus ocrelizumab on patients with PPMS.

A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS

This project is being done to understand how well patients respond to cladribine tablets. This is an observational study.

The purpose of this study is to determine if the study drug called ALZ-801 is safe, if it is well tolerated, and if it is effective in treating AD. It is a twice a day oral medication that is taken with meals.

The purpose of this study is to learn more about the use of the study drug, simufilam, for the treatment of Alzheimer’s disease. We want to test that it is safe and to find out whether it can slow down the advance of Alzheimer’s disease.

This project is being done to determine if the experimental drug AL001 is effective and safe in treating individuals who have a known progranulin gene mutation that causes FTD, when compared to placebo (a solution that contains no active AL001 drug).

The purpose of this research is to identify the most appropriate treatment strategy for people with multiple sclerosis (MS), especially shortly after diagnosis when it may be most possible to increase a patient’s chance for preventing longer-term disability.